InMed Pharmaceuticals Inc. stocks have been trading up by 152.68 percent amid heightened optimism from its latest clinical progress.
Click Here for a Millionaire's POV on Trading INM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Shares of INM ripped from under $0.70 to the $1.60s, showing a classic low-float momentum squeeze on strong volume.
- Recent intraday trading in INM featured wild swings between $1.25 and just above $2.00, highlighting elevated volatility and opportunity for nimble traders.
- InMed Pharmaceuticals Inc. is still a small revenue biotech with around $4.9M in annual sales and deep losses, keeping dilution risk on the radar.
- INM carries a strong cash position versus very low debt, giving the company runway despite negative earnings and cash burn.
- Traders are watching whether INM can hold above prior sub-$1 trading levels or if the spike fades back into the old range.
Live Update At 10:03:19 EDT: On Tuesday, May 19, 2026 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 152.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
INM is a classic micro-cap biotech story: tiny revenue, big losses, and a chart that occasionally goes parabolic. In the latest reported quarter, InMed Pharmaceuticals Inc. generated about $0.82M in revenue and roughly $4.9M over the trailing year. That’s small, but it is real revenue, not just a story.
Margins are brutal. INM is running ebit margins around -170%, with profit metrics deep in the red and a recent quarterly net loss of about $2.0M, or roughly -$0.51 per share. For traders, that means INM is not a value play; it’s a volatility and catalyst vehicle.
More Breaking News
- RGTI Stock Pulls Back As Quantum Trading Setup Emerges
- MNDY Stock Surges As AI Work Platform Fuels Breakout
- SLNH Stock Faces New Resale Overhang As Volatility Builds
- GCTS Stock Pops On Heavy Volume As Traders Scan Risky Balance Sheet
The balance sheet, however, shows some strength. InMed Pharmaceuticals Inc. reports roughly $6.9M in cash, working capital over $7.3M, and total liabilities near $1.6M, with debt-to-equity at only 0.06. That low leverage and a current ratio near 5.9 suggest INM has breathing room, even while burning about $2.4M in operating cash over the period. Valuation metrics like price-to-book around 0.19 and price-to-sales near 0.4 tell traders the market is heavily discounting the stock, which often sets the stage for sharp sentiment-driven spikes.
Why Traders Are Watching INM Price Action
The main story right now is the chart. INM spent weeks grinding in a tight band around $0.65–$0.75. Then it exploded. On the latest session, InMed Pharmaceuticals Inc. opened at $1.79 after previously closing under $0.70, ran to $1.80, and still finished in the high $1.60s. That’s more than a 100% move in a single day, even after pulling back from the highs.
Zoom in to the 5‑minute chart and you see exactly why active traders love this kind of action. Pre-market, INM whipped between roughly $1.25 and just above $2.00, with one push taking it over $2.09 before sellers smacked it back down. After the open, the stock dipped toward $1.31, then reclaimed the $1.60s into the close. That’s a full intraday range that rewards disciplined dip buyers and punishes anyone chasing late.
From a swing perspective, INM has shifted character. The stock was choppy but contained below $0.80 for most recent sessions. The latest breakout through that zone and the psychological $1.00 level signals new eyes on the name. For many short-term traders, the key question is simple: does InMed Pharmaceuticals Inc. build a new base above $1.00, or does it fade back into the old range?
Because the fundamentals of INM—negative earnings, high cash burn, minimal sales—have not suddenly transformed, this move looks more like a technical and sentiment-driven breakout than a long-term re‑rating. That’s fine for traders. It means you focus on price levels, volume, and clear risk rather than trying to guess long-term value.
Conclusion
INM is doing what small-cap biotechs do best: moving fast, with little warning, and punishing anyone who trades without a plan. The company behind the ticker, InMed Pharmaceuticals Inc., still shows steep losses, heavy negative returns on equity, and a free cash flow burn of about $2.4M over the recent period. Yet it also has cash, low debt, and a discounted valuation, which keeps the door open for more sharp price swings when traders wake up to the chart.
If INM holds above the breakout zone and builds higher lows, momentum traders will keep it on watch for more push attempts toward the recent $2.00 area and beyond. If it cracks back under the $1.00 region, that tells you the latest spike was just another one‑day wonder. Either way, the price action in InMed Pharmaceuticals Inc. is the main signal; the fundamentals simply frame the risk. For those who feel FOMO creeping in on these kinds of volatile moves, it helps to remember that, as Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.”
For active traders studying INM, the message is the same one Tim Sykes pounds into his students: “Patterns repeat, but only for those who study them relentlessly and cut losses without mercy.” Use the wild swings in InMed Pharmaceuticals Inc. as a training ground — not as a lottery ticket — and let the chart, not hope, guide your trading decisions.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.